Dear Editor,

We read with great interest the article “Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease” by Gillmeyer et al.1 Here, the authors sought to test in a real-world scenario the effect of pulmonary vasodilator therapy on patients with pulmonary hypertension (PH) due to left heart disease (Group 2 of the 6th World Symposium on Pulmonary Hypertension classification) and PH associated with chronic lung disease (Group 3).2 The study performed a retrospective cohort analysis and nested case control analysis of 132,552 Medicare-eligible Veterans who were attended within the Veterans Administration Healthcare (VA) system.

The study findings of increased risk of death or organ failure in patients exposed to pulmonary vasodilators are consistent with findings from randomized clinical trials3–6 and other cohort studies and “real-world scenarios”, as quoted by the authors. However, a very important lesson from over two decades of studies is that proper phenotyping of pulmonary vascular disease is key to assess risk of progression of disease. For instance, while PH is common in patients with chronic lung disease, it is usually mild to moderate.7 A different phenotype of PH has been described in patients with chronic obstructive pulmonary disease (COPD),8 with a predominant vascular phenotype characterized by severe hemodynamics, decreased cardiac output, and impaired ventriculo-vascular coupling, and it is been hypothesized that this subgroup of patients could benefit from pulmonary vasodilators. Vitulo et al.,9 showed a potential benefit of sildenafil in patients with severe PH associated with COPD. The recent INCREASE study10 (phase 3 randomized control trial of inhaled Treprostinil in patients with PH associated with interstitial lung disease) met its primary end point and demonstrated improvements in six-minute walk distance, brain natriuretic peptide (NT-proBNP), and lower risk of clinical worsening. In Group 2, vascular disease is phenotyped as isolated post-capillary PH and combined pre- and post-capillary PH, and these phenotypes have bearing on the outcomes of vasodilator treatments on these patients;11–13 indeed, the recent HELP trial identified a subgroup of patients with post-capillary PH and heart failure with preserved ejection fraction who benefited from Levosimendan.14 As we progress in the study of these phenotypes, both in Group 2 and Group 3 PH, we might understand which mechanisms produce these subtle but clear differences in response to vasodilator treatment.

In the study by Gillmeyer et al., given the nature of the study, data are very limited on the definitive presence of PH or its severity. It is indeed noteworthy that so many patients in the VA have been treated with pulmonary vasodilators without having been properly phenotyped with a right heart catheterization; all the more so as we know how challenging the interpretation of echocardiography can be,15 especially in the setting of Group 2 and Group 3 PH.7 It is thus
difficult to glean from this data whether PH was effectively present in two-thirds of patients, let alone know its severity. It is true that in Group 2 and Group 3 PH, right heart catheterization is only recommended when the diagnosis has the potential to inform treatment (heart or lung transplantation, inclusion in a randomized controlled trial in the case of severe PH, risk factors for Group 1 or Group 4 PH), and this has been historically one of the reasons why studying these patients has been so difficult; on the other hand, in the absence of a clear treatment option, it stands to reason that this invasive procedure be restricted to the relevant cases.

We fully agree with the authors of the paper that the use of pulmonary vasodilators in Group 2 and Group 3 PH should be confined to randomized-controlled trials, not only in order to carefully monitor patients and gather data on the numerous safety concerns, but also in order to generate new, reliable evidence on these disparate and elusive, yet deadly diseases. We also think that the use of registries will help garner more information on “real-world” scenarios and confirm on retrospective cohorts the results obtained in randomized-controlled trials, provided we are careful to study disease groups and subgroups appropriately, avoiding the temptation of lumping them together in a bigger cohort which will inevitably mixed pears with apples.

Finally, in full agreement with the recommendations for future directions in research on Group 3 PH, we call for studies that delve deeper into these heterogeneous groups of diseases. After the low-definition group photos, we believe it is time to zoom in the picture to gather a better understanding of what exactly is killing the different subgroups within Group 2 and Group 3 PH patients.

Contributions
L.P. conceived the idea; L.P. and S.S. developed it; R.J.B., D.R.-C., P.V. and J.W. contributed to the manuscript; and L.P. and S.S. finalized it.

Conflict of interest
S.S.: Consultancy fees from Janssen Pharmaceutical Companies of Johnson & Johnson, United Therapeutics, Bayer Pharmaceuticals; research/grant support from Chest Foundation (ILD research grant); Scientific medical advisor fees for United Therapeutics, Altavant Sciences, and Liquidia; and Speaker’s bureau fees from Janssen Pharmaceutical Companies of Johnson & Johnson, Bayer, and United Therapeutics.

L.P.: no conflicts of interest to disclose.
R.J.B.: no conflicts of interest to disclose.
D.R.-C.: no conflicts of interest to disclose.
P.V.: no conflicts of interest to disclose.
J.W.: no conflicts of interest to disclose.

Funding
This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

References
1. Gillmeyer K, Miller DR, Glickman ME, et al. Outcomes of pulmonary vasodilator use in Veterans with pulmonary hypertension associated with left heart disease and lung disease. *Pulm Circ*. Epub ahead of print 2021. DOI: 10.1177/20458940211001714.
2. Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 2019; 53: 1–20.
3. Hoendermis ES, Liu LCY, Hummel YM, et al. Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. *Eur Heart J* 2015; 36: 2565–2573.
4. Corte TJ, Keir GJ, Dimopoulos K, et al. Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. *Am J Respir Crit Care Med* 2014; 190: 208–217.
5. Blanco I, Santos S, Geo J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. *Eur Respir J* 2013; 42: 982–992.
6. Goudie AR, Lipworth BJ, Hopkinson PJ, et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomized, double-blind, parallel-group, placebo-controlled trial. *Lancet Respir Med* 2014; 2: 293–300.
7. Nathan SD, Barberà JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. *Eur Respir J*. Epub ahead of print 2018. DOI: 10.1183/13993003.01914-2018.
8. Kovacs G, Agusti A, Barberà JA, et al. Pulmonary vascular involvement in chronic obstructive pulmonary disease. Is there a pulmonary vascular phenotype? *Am J Respir Crit Care Med* 2018; 198: 1000–1011.
9. Vitulo P, Stanzioia A, Confalonieri M, et al. Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: a randomized controlled multicenter clinical trial. *J Heart Lung Transplant* 2017; 36: 166–174.
10. Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. *N Engl J Med*. Epub ahead of print 2021. DOI: 10.1056/NEJMoa2008470.
11. Kramer T, Dumitrescu D, Gerhardt F, et al. Therapeutic potential of phosphodiesterase type 5 inhibitors in heart failure with preserved ejection fraction and combined post- and pre-capillary pulmonary hypertension. *Int J Cardiol* 2019; 283: 152–158.
12. Palacios GMS, Schmidt C and Wichman T. Targeted therapy with phosphodiesterase 5 inhibitors in patients with pulmonary hypertension due to heart failure and elevated pulmonary vascular resistance: a systematic review. Epub ahead of print 2020. DOI: 10.1177/2045894020948780.
13. Caravita S, Faini A, Araujo SCD, et al. Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: role of the pre-capillary component. *PLoS One* 2018; 13: e0199164. doi: 10.1371/journal.pone.0199164.

14. Burkhoff D, Borlaug BA, Shah SJ, et al. Levosimendan improves hemodynamics and exercise tolerance in PH-HFpEF: results of the randomized placebo-controlled HELP trial. *JACC Hear Fail* 2021; i: 1–11.

15. Rich JD, Shah SJ, Swamy RS, et al. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension implications for clinical practice. *Chest* 2011; 139: 988–993.

16. Nathan SD, Behr J, Collard HR, et al. Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. *Lancet* 2019; 7: 10–18.

17. Vachiéry J, Delcroix M, Al-hiti H, et al. Macitentan in pulmonary hypertension due to left ventricular dysfunction. *Eur Respir J*. Epub ahead of print 2018. DOI: 10.1183/13993003.01886-2017.